NCT03926130MirikizumabMIRICrohn’s disease
… from patients randomised to MIRI in the Phase 3 VIVID-1 study (NCT03926130) who attained endoscopic response at week 52 (W52) and continue…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT03926130 ×
NCT03926130
This institution is selected. Its supporting articles are shown below.